Belfort PLF, Tadeu VR, Fortes BBVAC

Idioma: Portugués
Referencias bibliográficas: 10
Paginas: 52-54
Archivo PDF: 373.15 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Tanetsakunwatana T, Tovanabutra N, Kanchanarattanakorn K, Chiewchanvit S. Pentoxifylline as add-on therapy in the treatment of moderate to severe psoriasis. Chiang Mai Med J. 2013; 52 (3-4): 43-50.

2. Çakmak SK, Çakmak A, Gönül M, Kiliç A, Gül Ü. Pentoxifylline use in dermatology. Inflamm Allergy Drug Targets. 2012; 11 (6): 422-432.

3. Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Dovepress. 2016; 6: 93-104.

4. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008; 181 (7): 4733-4741.

5. Hassan I, Dorjay K, Anwar P. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014; 5 (4): 510-516.

6. Arruda LHF, Campbell GAM, Takahashi MDF. Psoriasis. An Bras Dermatol. 2001; 76: 141-167.

7. Magalhães GM. Psoríase e pentoxifilina: ensaio clínico duplo cego, randomizado e controlado - avaliação clínica, histopatológica e imunohistoquímica. An Bras Dermatol. 2005; 80 (4).

8. Magela-Magalhães G, Coelho da Silva Carneiro S, Peisino do Amaral K, de Freire-Cássia F, Machado-Pinto J, Cuzzi T. Psoriasis and pentoxifylline: a clinical, histopathologic, and immunohistochemical evaluation. Skinmed. 2006; 5 (6): 278-284.

9. Carneiro SC, Medeiros R, Magalhães GM, Alves C, Cuzzi T, Sotto MN. Ação da pentoxifilina nos dendrócitos dérmicos FXIIIa de placas de psoríase. An Bras Dermatol. 2005; 80 (Suppl 3): S314-S322.

10. el-Mofty M, el-Darouti M, Rasheed H, Bassiouny DA, Abdel-Halim M, Zaki NS et al. Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative. J Dermatolog Treat. 2011; 22 (1): 31-37.